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OVERVIEW
The human brain- and retinal-resident
microRNA-146a (miRNA-146a) is an
inducible, NF-kB-regulated small non-
coding RNA (sncRNA) whose increased
expression is associated with pro-
inflammatory neurodegeneration in
Alzheimer’s disease (AD), age-related
macular degeneration (AMD), and prion
disease (PrD). In AD, AMD, and PrD
miRNA-146a modulates the innate-
immune response, inflammation, and the
microglial activation state. This short paper
will review and comment on the role of
miRNA-146a signaling and how it under-
lies common molecular-pathogenetic
mechanisms in each of these progressive,
age-related neurological disorders for
which there are currently no effective
treatment or cure.
microRNA-146a




org/Genes/GC_MIR146B.html), is one of
the most intensively studied small non-
coding RNAs (sncRNAs) in all of human
neurobiology. Encoded from a single locus
at chromosome 5q33.3 in humans and at
chromosome 11q in mice, miRNA-146a
is a rapidly induced, pro-inflammatory
miRNA with a relatively short half-life
of about 1.5–2 h in human brain cells
and tissues (1–4). This unique mem-
ber of the miRNA-146 gene family was
initially described as being significantly
up-regulated after microbial endotoxin,
lipopolysaccharide (LPS), or cytokine
stimulation of THP1 cells (monocytes;
originally derived from an acute monocytic
leukemia patient) and under transcrip-
tional control by NF-κB; shortly thereafter
this inducible miRNA-146a was found to
be up-regulated by metal sulfate-generated
reactive oxygen species (ROS), by pro-
inflammatory cytokines (such as IL-1β and
TNFα) and amyloid peptides (such as Aβ42
peptides) in human primary neuronal-glial
(HNG) co-cultures and microglial (HMG)
cells (4–7). Each of these independent
studies showed the targeting of miRNA-
146a to the mRNAs encoding signaling
proteins involved in the innate immune
and inflammatory response, including
complement factor H (CFH) and the
interleukin-1 receptor-associated kinase 1
(IRAK-1; the gene partially responsible
for IL-1-induced up-regulation of the
transcription factor NF-kB; (1–4); see
below).
Sequencing and promoter analysis
of the human miRNA-146a gene sub-
sequently identified three functional and
conserved NF-κB binding sites upstream of
the miRNA-146a gene, and combined with
functionality and NF-kB-inhibition assays
was the first NF-κB-regulated miRNA gene
identified in the human brain and central
nervous system [CNS; (2–4)]. Interest-
ingly, while miRNA-146a is detectable
in mouse and human brain and CNS
tissues and primary HNG co-cultures,
the most significant miRNA-146a abun-
dances have been found to be in human
astroglial (HAG) and microglial (HMG)
cells, the later representing the “resident
scavenging macrophages” of the brain, and
key participants in the brain’s innate-
immune and inflammatory response
(3–9). While expressed modestly in the
brain and retina, miRNA-146a can be
induced 2- to 10-fold or more in cultured
brain cells where miRNA-146a is basally
expressed, after the application of several
different classes of physiological stressors
including treatments with herpes simplex
virus (HSV-1), neurotoxic metal sulfates
(such as aluminum sulfate at nanomo-
lar concentrations), microbial endotox-
ins including LPS, pro-inflammatory
cytokines or amyloid beta (Aβ)
peptides (1–5, 10).
Interestingly, human miRNA-146a
has a related miRNA-146b isotype
(miR-146b; hsa-miR-146b-5p; 5′-
UGAGAACUGAAUUCCAUAGGCU-3′;
59% A+U; NR_030169) encoded at
chromosome 10q24.32 (in mice on chro-
mosome 19q); these two miRNAs have
an identical seed (primary recognition)
region and differ by only two ribonu-
cleotides in the primary sequence of
their stem-loop secondary structures
(1–3, 10–12). Notably, it is a change
in just two nucleotides in the 3′ end,
from miRNA-146b (5′-UAGGCU-3′) to
miRNA-146a (5′-UGGGUU-3′), which
may confer enhanced specificity of
miRNA-146a for mRNA targets involved in
the innate-immune response of the CNS,
and/or the ability to be induced and/or
processed by different pro-inflammatory
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cytokines [(8, 9, 13); unpublished
observations].
ALZHEIMER’S DISEASE
According to the World Health Organi-
zation, the total number of people with
dementia worldwide is currently estimated
to be about 36 million, and this number is
expected to almost double by 2030, reach-
ing 66 million, and triple by 2050, reach-
ing 100 million (14). Alzheimer’s disease
(AD), the leading cause of this demen-
tia, is a progressive, age-related, and ulti-
mately fatal neurological disorder associ-
ated with dysfunctional gene expression in
the limbic system and entorhinal cortex
of the brain that drives amyloidogenesis,
pro-inflammatory signaling, and related
AD-type neuropathology (15–18). Of all
AD cases approximately 5% may be attrib-
uted to familial gene mutations while 95%
occur sporadically, i.e., are of idiopathic or
unknown origin (7, 14).
Amyloidogenesis involves the
progressive generation and aggregation
of 42 amino acid amyloid beta (Aβ42)
peptides and other amyloidogenic pep-
tides into dense, insoluble senile plaques
whose recognition by brain cell microglia
instigates a pro-inflammatory microglial
response and the release of reactive oxy-
gen species (ROS) and pro-inflammatory
cytokines (3, 4, 7, 19). The first evi-
dence of sncRNA involvement in sporadic
AD reported mis-regulated levels of a
polyadenylated brain cytoplasmic ~200
nucleotide (BC200) sncRNA in cases of
AD, non-AD dementia, and controls (20).
BC200 was found to be down-regulated
and reflective of deficits in the abundance
of neuron-specific transcripts, consistent
with the idea that sporadic AD was char-
acterized by a deficit in the generation of
primary brain gene transcription prod-
ucts (20–25). The next reports of specific
miRNA up-regulation in AD brain and
blood serum did not appear until about
15 years later wherein a brain abundant
miRNA-146a was one of the first miRNAs
found (i) to be elevated in anatomical
regions of the brain affected by the AD
process but not in control regions (such
as the thalamus and brain stem) of the
same brain, or (ii) to be induced by
AD-relevant stressors, such as the pro-
inflammatory cytokines interleukin 1-beta
(IL-1β) or tissue necrosis factor alpha
(TNFα) and Aβ42 peptides, or combi-
nations of these noxious factors which
are pathologically abundant in the AD
brain (6, 7, 21–25).
To date confirmed targets of miRNA-
146a include key AD-relevant members of
the innate-immune system including the
155 kDa sialic-acid containing glycopro-
tein immune repressor complement fac-
tor H (CFH), the membrane spanning
beta-amyloid precursor protein (βAPP)-
associated TSPAN12, and the inflam-
mation mediator interleukin receptor-
associated kinase IRAK-1 (1). Interestingly,
pathologically up-regulated miRNA-146a,
as seen in AD brain or pathologically
stressed primary HNG co-cultures results
in (i) CFH down-regulation and a stimula-
tion of innate immune and inflammatory
pathways (10, 25); (ii) down-regulation
of TSPAN12 that drives a propensity for
the massive production of Aβ42 pep-
tides from βAPP (26); and (iii) down-
regulation of IRAK-1 with a compensatory
up-regulation of IRAK-2 (1, 4, 10). It
is important to point out (i) that mul-
tiple NF-kB-regulated miRNAs such as
miRNA-9, miRNA-34a, miRNA-125b, and
miRNA-155 may have additional or ancil-
lary roles in the pathological regulation
of CFH, TSPAN12, and IRAK-1 in the
AD brain and (ii) that miRNA abun-
dance and complexity varies among both
human cell types and tissues, and there
are also obvious variations in pathogenic




Age-related macular degeneration (AMD)
is an advancing, proliferative degenera-
tion of retinal pigment epithelial, ganglion,
and other related cells of the human mac-
ula, a highly specialized centralized region
of the retina, resulting in the progressive
loss of vision near the center of the
visual field (8, 30–34). AD and AMD
share many common pathological path-
ways including the appearance of dense,
insoluble, Aβ42 peptide-enriched lesions
(called drusen in AMD and called senile
plaques in AD), a disruption in com-
plement signaling including CFH loss-
of-function or down-regulation, and the
up-regulation of pro-inflammatory sncR-
NAs that include, prominently, miRNA-
146a (32–35). Importantly, the com-
mon neuroectodermal origins of the
limbic system, neocortex, and retina
may predispose each of these highly
integrated, multi-neuronal layered struc-
tures to progressive age-related functional
impairment, including the involvement of
shared pathogenic pathways that drive the
development and“spreading”of amyloido-
genesis and pro-inflammatory neurode-
generation.
As fore-mentioned, CFH plays an
integral role in the regulation of the
complement-mediated immune system
that is involved in the first line of microbial
defense against many pathogens, innate-
immune complex processing, and pro-
gramed cell death. CFH is emerging as
an unexpected key player in both AD and
AMD (10, 25, 30, 31, 36, 37). Activation
of the complement system results in a
proteolytic cascade eventually forming the
membrane attack complex (MAC) leading
to cell membrane perforation, lysis, and the
dissolution of cellular contents, and a solu-
ble brain- and retinal-abundant CFH nor-
mally protects host cells from unrestrained
complement activation (31–34, 36).
Interestingly, the Y402H CFH loss-of-
function mutation linked to AMD in many
human populations may produce suffi-
cient amounts of a non-functioning CFH,
and this may be pathologically equiva-
lent to insufficient amounts of a func-
tional CFH protein, as is observed in spo-
radic AD, and perhaps other inflamma-
tory degenerative and dementing diseases
including Down’s syndrome [Trisomy 21;
(10, 25, 37)]. Indeed common CFH deficits
in AMD and AD underscore the impor-
tant role of innate-immune system regu-
lation and complement signaling in these
age-related progressive, inflammatory neu-
rodegenerative diseases of the CNS. It is
further noteworthy that human prion pro-
tein (PrP), an endogenous glycosylphos-
phatidylinositol (GPI)-anchored or trans-
membrane protein expressed in neurons
strongly interacts with CFH, and the CFH-
PrP complex pathologically super-activates
complement via the classical and alter-
native pathways, leading to MAC forma-
tion and progressive cell dysfunction and
ultimately, cell death (38).
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PRION DISEASE
Prion diseases encompass a family of self-
replicating prion protein (PrP) amyloid
and related aggregates – driving pathophys-
iological conditions that are the primary
causative factor of a number of progressive
neurological diseases in mammals includ-
ing humans (39–42). The first report of
up-regulated miRNA-146a in prion dis-
ease was published in 2008 in a murine
model of scrapie, and miRNA-146a was
subsequently reported to be significantly
up-regulated in the two rare human prion
diseases sporadic Creutzfeldt-Jakob dis-
ease (sCJD) and Gerstmann–Straussler–
Scheinker (GSS) syndrome (40–42). In
prion disease miRNA-146a and other
NF-kB-up-regulated, inducible miRNAs
have been found to target the expres-
sion of genes involved in intracellular
protein-degradation pathways and sig-
naling pathways related to cell death,
synapse function and neurogenesis as
well as brain genes modulating microglial
function by regulating their activation
state during PrP-induced neurodegenera-
tion (39–42). Interestingly, human prion
diseases such as sCJD and GSS are
highly similar to neurological diseases
such as AD involving a significant pro-
inflammatory and amyloidogenic compo-
nent linked to progressive memory, cogni-
tive, and behavioral deficits in the affected
patient (39, 41).
CONCLUDING REMARKS
Our perceptions on the relevance and gene
expression mechanisms of up-regulated
miRNA-146a signaling in progressive,
pathologically similar, human neurologi-
cal diseases continue to evolve. It is now
generally accepted that the primary mode
of pathological miRNA action in the brain
is to recognize and bind to complemen-
tary ribonucleotide sequences in the 3′-
prime un-translated region (3′-UTR) of
their target messenger RNAs and in doing
so, down-regulate their expression (1–3,
10–13, 40, 43). Increased expression of
miRNA-146a and down-regulation in the
expression of miRNA-146a target genes
are strongly associated with AD, AMD,
and PrD disease phenotype and symp-
tomology, both in cultured cell or ani-
mal models for that disease and in the
human disease itself (31, 37, 44). miRNA-
146a or families of other miRNA-146a-
related miRNAs may orchestrate multi-
ple deficits in multiple mRNA targets to
coordinately affect the expression of fami-
lies of brain-relevant innate-immune and
inflammatory genes that are related in
function in disease initiation,development,
and propagation. It is noteworthy that
the speciation and complexity of miRNA-
146a-related families may differ slightly
among different types of CNS cells and
tissues, and even among the same cells
and tissues of different human populations
(25–29). The conclusion of this paper is
that common neurodegenerative diseases of
the human CNS and retina including AD,
AMD, and PrD, each appear to utilize an
overexpressed miRNA-146a in their disease
mechanism, and that this anomaly com-
monly disrupts homeostatic innate-immune
signaling to promote an inflammatory
phenotype.
While pro-inflammatory miRNAs such
as miRNA-146a are generally consid-
ered to be important epigenetic, post-
transcriptional regulators of gene expres-
sion in both health and disease, it is not
often appreciated that these sncRNAs: (i)
are very highly selected in their ribonu-
cleotide sequence in mouse and human and
exhibit remarkable brain cell and CNS tis-
sue specificity; (ii) are the smallest yet iden-
tified ribonucleic acid carriers of highly
specific, genetic regulatory information in
the human brain and CNS; (iii) are the
most abundant extracellular, highly sol-
uble nucleic acids contained in human
circulatory fluids including the extracel-
lular fluid (ECF), the cerebrospinal fluid
(CSF), and blood serum; and (iv) as such
may be capable of spreading genetic sig-
naling information, both homeostatic and
pathogenic, among neighboring CNS cells
and tissues (20, 44–47). Anti-miRNA-146a
(AM-146a) strategies aimed at quenching
pathogenic miRNA effects have worked
surprisingly well in cell cultures in vitro,
but their efficacy in progressive neuro-
logical disease awaits additional animal
experimentation and human clinical tri-
als. Investigations are further warranted
for the potential utility of circulating
miRNA-146a and its related family mem-
bers as potential diagnostic biomarkers for
AD, AMD, PrD, and perhaps other age-
related human neurological diseases with
an innate-immune and pro-inflammatory
component (31, 48–50).
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